- Home
- PMVP vs QNCX Comparison
PMVP vs QNCX Comparison
Compare PMVP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- QNCX
- Stock Information
- Founded
- PMVP 2013
- QNCX 2012
- Country
- PMVP United States
- QNCX United States
- Employees
- PMVP N/A
- QNCX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- QNCX Health Care
- Exchange
- PMVP Nasdaq
- QNCX Nasdaq
- Market Cap
- PMVP 85.5M
- QNCX 92.3M
- IPO Year
- PMVP 2020
- QNCX 2019
- Fundamental
- Price
- PMVP $1.51
- QNCX $1.88
- Analyst Decision
- PMVP Strong Buy
- QNCX Strong Buy
- Analyst Count
- PMVP 4
- QNCX 3
- Target Price
- PMVP $5.75
- QNCX $9.67
- AVG Volume (30 Days)
- PMVP 196.4K
- QNCX 286.7K
- Earning Date
- PMVP 11-07-2024
- QNCX 11-13-2024
- Dividend Yield
- PMVP N/A
- QNCX N/A
- EPS Growth
- PMVP N/A
- QNCX N/A
- EPS
- PMVP N/A
- QNCX N/A
- Revenue
- PMVP N/A
- QNCX N/A
- Revenue This Year
- PMVP N/A
- QNCX N/A
- Revenue Next Year
- PMVP N/A
- QNCX N/A
- P/E Ratio
- PMVP N/A
- QNCX N/A
- Revenue Growth
- PMVP N/A
- QNCX N/A
- 52 Week Low
- PMVP $1.40
- QNCX $0.51
- 52 Week High
- PMVP $3.47
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PMVP 38.59
- QNCX 52.02
- Support Level
- PMVP $1.55
- QNCX $1.80
- Resistance Level
- PMVP $1.61
- QNCX $2.09
- Average True Range (ATR)
- PMVP 0.07
- QNCX 0.21
- MACD
- PMVP -0.01
- QNCX -0.05
- Stochastic Oscillator
- PMVP 18.18
- QNCX 27.01
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.